Tumor-Infiltrating Lymphocytes and Immune Response in HER2-Positive Breast Cancer
Human epidermal growth factor receptor 2–positive (HER2-positive) breast cancer accounts for 15 to 25% of breast cancer cases. Although therapies based on the use of monoclonal anti-HER2 antibodies present clinical benefit for a subtype of patients with HER2-positive breast cancer, more than 50% of...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-12-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/24/6034 |
| _version_ | 1797461094248218624 |
|---|---|
| author | Melani Luque Marta Sanz-Álvarez Miriam Morales-Gallego Juan Madoz-Gúrpide Sandra Zazo Carolina Domínguez Alicia Cazorla Yann Izarzugaza Juan Luis Arranz Ion Cristóbal Federico Rojo |
| author_facet | Melani Luque Marta Sanz-Álvarez Miriam Morales-Gallego Juan Madoz-Gúrpide Sandra Zazo Carolina Domínguez Alicia Cazorla Yann Izarzugaza Juan Luis Arranz Ion Cristóbal Federico Rojo |
| author_sort | Melani Luque |
| collection | DOAJ |
| description | Human epidermal growth factor receptor 2–positive (HER2-positive) breast cancer accounts for 15 to 25% of breast cancer cases. Although therapies based on the use of monoclonal anti-HER2 antibodies present clinical benefit for a subtype of patients with HER2-positive breast cancer, more than 50% of them are unresponsive to targeted therapies or they eventually relapse. In recent years, reactivation of the adaptive immune system in patients with solid tumors has emerged as a therapeutic option with great potential for clinical benefit. Since the approval of the first treatment directed against HER2 as a therapeutic target, the range of clinical options has expanded greatly, and, in this sense, cellular immunotherapy with T cells relies on the cytotoxicity generated by these cells, which ultimately leads to antitumor activity. Lymphocytic infiltration of tumors encompasses a heterogeneous population of immune cells within the tumor microenvironment that exhibits distinct patterns of immune activation and exhaustion. The prevalence and prognostic value of tumor-infiltrating lymphocyte (TIL) counts are associated with a favorable prognosis in HER2-positive breast cancers. This review discusses emerging findings that contribute to a better understanding of the role of immune infiltrates in HER2-positive breast cancer. In addition, it summarizes the most recent results in HER2-positive breast cancer immunotherapy and anticipates which therapeutic strategies could be applied in the immediate future. |
| first_indexed | 2024-03-09T17:14:32Z |
| format | Article |
| id | doaj.art-9139ebb8800845d79b6e178054ef00c5 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T17:14:32Z |
| publishDate | 2022-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-9139ebb8800845d79b6e178054ef00c52023-11-24T13:45:05ZengMDPI AGCancers2072-66942022-12-011424603410.3390/cancers14246034Tumor-Infiltrating Lymphocytes and Immune Response in HER2-Positive Breast CancerMelani Luque0Marta Sanz-Álvarez1Miriam Morales-Gallego2Juan Madoz-Gúrpide3Sandra Zazo4Carolina Domínguez5Alicia Cazorla6Yann Izarzugaza7Juan Luis Arranz8Ion Cristóbal9Federico Rojo10Department of Pathology, Fundación Jiménez Díaz University Hospital Health Research Institute (IIS—FJD, UAM)—CIBERONC, 28040 Madrid, SpainDepartment of Pathology, Fundación Jiménez Díaz University Hospital Health Research Institute (IIS—FJD, UAM)—CIBERONC, 28040 Madrid, SpainDepartment of Pathology, Fundación Jiménez Díaz University Hospital Health Research Institute (IIS—FJD, UAM)—CIBERONC, 28040 Madrid, SpainDepartment of Pathology, Fundación Jiménez Díaz University Hospital Health Research Institute (IIS—FJD, UAM)—CIBERONC, 28040 Madrid, SpainDepartment of Pathology, Fundación Jiménez Díaz University Hospital Health Research Institute (IIS—FJD, UAM)—CIBERONC, 28040 Madrid, SpainDepartment of Pathology, Fundación Jiménez Díaz University Hospital Health Research Institute (IIS—FJD, UAM)—CIBERONC, 28040 Madrid, SpainDepartment of Pathology, Fundación Jiménez Díaz University Hospital Health Research Institute (IIS—FJD, UAM)—CIBERONC, 28040 Madrid, SpainMedical Oncology Department, Fundación Jiménez Díaz University Hospital, 28040 Madrid, SpainMedical Oncology Department, Fundación Jiménez Díaz University Hospital, 28040 Madrid, SpainCancer Unit for Research on Novel Therapeutic Targets, Oncohealth Institute, IIS-Fundación Jiménez Díaz-UAM, 28040 Madrid, SpainDepartment of Pathology, Fundación Jiménez Díaz University Hospital Health Research Institute (IIS—FJD, UAM)—CIBERONC, 28040 Madrid, SpainHuman epidermal growth factor receptor 2–positive (HER2-positive) breast cancer accounts for 15 to 25% of breast cancer cases. Although therapies based on the use of monoclonal anti-HER2 antibodies present clinical benefit for a subtype of patients with HER2-positive breast cancer, more than 50% of them are unresponsive to targeted therapies or they eventually relapse. In recent years, reactivation of the adaptive immune system in patients with solid tumors has emerged as a therapeutic option with great potential for clinical benefit. Since the approval of the first treatment directed against HER2 as a therapeutic target, the range of clinical options has expanded greatly, and, in this sense, cellular immunotherapy with T cells relies on the cytotoxicity generated by these cells, which ultimately leads to antitumor activity. Lymphocytic infiltration of tumors encompasses a heterogeneous population of immune cells within the tumor microenvironment that exhibits distinct patterns of immune activation and exhaustion. The prevalence and prognostic value of tumor-infiltrating lymphocyte (TIL) counts are associated with a favorable prognosis in HER2-positive breast cancers. This review discusses emerging findings that contribute to a better understanding of the role of immune infiltrates in HER2-positive breast cancer. In addition, it summarizes the most recent results in HER2-positive breast cancer immunotherapy and anticipates which therapeutic strategies could be applied in the immediate future.https://www.mdpi.com/2072-6694/14/24/6034HER2-positive breast cancerimmunotherapytumor-infiltrating lymphocytes |
| spellingShingle | Melani Luque Marta Sanz-Álvarez Miriam Morales-Gallego Juan Madoz-Gúrpide Sandra Zazo Carolina Domínguez Alicia Cazorla Yann Izarzugaza Juan Luis Arranz Ion Cristóbal Federico Rojo Tumor-Infiltrating Lymphocytes and Immune Response in HER2-Positive Breast Cancer Cancers HER2-positive breast cancer immunotherapy tumor-infiltrating lymphocytes |
| title | Tumor-Infiltrating Lymphocytes and Immune Response in HER2-Positive Breast Cancer |
| title_full | Tumor-Infiltrating Lymphocytes and Immune Response in HER2-Positive Breast Cancer |
| title_fullStr | Tumor-Infiltrating Lymphocytes and Immune Response in HER2-Positive Breast Cancer |
| title_full_unstemmed | Tumor-Infiltrating Lymphocytes and Immune Response in HER2-Positive Breast Cancer |
| title_short | Tumor-Infiltrating Lymphocytes and Immune Response in HER2-Positive Breast Cancer |
| title_sort | tumor infiltrating lymphocytes and immune response in her2 positive breast cancer |
| topic | HER2-positive breast cancer immunotherapy tumor-infiltrating lymphocytes |
| url | https://www.mdpi.com/2072-6694/14/24/6034 |
| work_keys_str_mv | AT melaniluque tumorinfiltratinglymphocytesandimmuneresponseinher2positivebreastcancer AT martasanzalvarez tumorinfiltratinglymphocytesandimmuneresponseinher2positivebreastcancer AT miriammoralesgallego tumorinfiltratinglymphocytesandimmuneresponseinher2positivebreastcancer AT juanmadozgurpide tumorinfiltratinglymphocytesandimmuneresponseinher2positivebreastcancer AT sandrazazo tumorinfiltratinglymphocytesandimmuneresponseinher2positivebreastcancer AT carolinadominguez tumorinfiltratinglymphocytesandimmuneresponseinher2positivebreastcancer AT aliciacazorla tumorinfiltratinglymphocytesandimmuneresponseinher2positivebreastcancer AT yannizarzugaza tumorinfiltratinglymphocytesandimmuneresponseinher2positivebreastcancer AT juanluisarranz tumorinfiltratinglymphocytesandimmuneresponseinher2positivebreastcancer AT ioncristobal tumorinfiltratinglymphocytesandimmuneresponseinher2positivebreastcancer AT federicorojo tumorinfiltratinglymphocytesandimmuneresponseinher2positivebreastcancer |